CJC-1295 questions
The same name can conceal different ingredients. These answers keep the forms and the evidence separate.
What does the CJC-1295 name cover?
CJC-1295 is a synthetic peptide designed to act like growth hormone-releasing hormone, the signal that helps the pituitary gland release growth hormone. The DAC form carries an addition that binds albumin in blood. That binding helps explain its persistence over several days.
The substance called CJC-1295 without DAC lacks that addition. FDA's assessment treats the forms as different active ingredients and describes confusing naming across related substances. A familiar name is not enough to establish that two preparations contain the same ingredient or have the same behavior in people.
Has CJC-1295 been shown to improve health?
Small human studies showed changes in growth hormone and IGF-1 with the DAC form. They did not demonstrate improved sleep, reduced fat, increased muscle, or slower aging. A hormone change can establish that a pathway responded without establishing a useful treatment effect.
The early healthy-adult study was a pharmacology investigation. Results from people without the condition being treated also cannot establish effectiveness for that condition. Reports from communities remain anecdotes, even when they describe outcomes that sound biologically plausible.
Does adding ipamorelin strengthen the evidence?
No. Ipamorelin is a different peptide that acts at the ghrelin receptor and can stimulate growth hormone release. Combining pathways provides a research rationale, but a rationale is not a trial of a fixed combination. No controlled human study of the CJC-1295/ipamorelin blend establishes its benefits or an appropriate regimen.
FDA's ipamorelin evaluation addresses that ingredient's own evidence and safety concerns. Findings for either ingredient alone cannot determine the risks of the combination. The DAC distinction still matters when a product contains more than one peptide.
Reading the older CJC-1295 papers
The central human reports were published in 2006 and 2009. Their age does not erase what they measured, but later claims still need evidence of their own. Reading an old paper means checking the form, participants, outcome, and observation period before applying its result elsewhere.
A study of growth hormone pulses found that pulses persisted during CJC-1295 exposure. A later blood-protein study examined markers of hormone-system activation. Neither was a trial of sleep quality or exercise recovery. The research page follows these reports in context rather than treating the publication dates as evidence of clinical progress.
Did the FDA clear CJC-1295?
CJC-1295 has no FDA-approved medical use. On FDA's page current as of April 22, 2026, it appears among bulk substances whose nominations were withdrawn. The nominators withdrew their requests; that does not mean FDA cleared the compound, approved compounding, or moved it into Category 1.
FDA retains safety concerns beside the entry and gives no individual withdrawal date. Ipamorelin acetate has a different detail: the page lists a withdrawn nomination and also retains a Category 2 entry for the 503B outsourcing-facility policy. The two ingredients' statuses cannot be summarized as a blanket clearance.
What is known about safety?
The short human studies describe reactions such as headache, flushing, and local administration-site reactions. FDA also discusses cardiovascular reactions, immune concerns, and potential risks associated with increased growth hormone activity. The small studies do not establish long-term safety.
No approved CJC-1295 label sets out a complete contraindication list. Pregnancy and childhood safety are unresolved. A history of cancer, glucose problems, or heart disease adds questions requiring a clinician's assessment. The safety discussion distinguishes reported reactions from concerns based on the pathway.
Is CJC-1295 allowed in tested sport?

The 2026 World Anti-Doping Agency list names CJC-1295 under section S2 and prohibits it at all times. The restriction covers competition and time outside competition. The fact that a compound stimulates the body's own hormone release does not exempt it from that rule.
Sport eligibility and medical safety are separate questions. A prohibited-list entry does not measure the likelihood of an adverse effect, and a prescription does not by itself settle an athlete's obligations. Athletes need advice from the relevant sport authority about the rules that apply to them.